An interim analysis of the SACHI study, investigating the combination of osimertinib and savolitinib for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer (NSCLC) in China, was published on January 1, 2026. This pivotal publication details early findings from the clinical trial comparing the combination therapy to chemotherapy.
Background
Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality globally. For patients with EGFR mutation-positive NSCLC, targeted therapies like osimertinib have significantly improved outcomes. However, resistance mechanisms often emerge, with MET amplification being a recognized pathway for acquired resistance to EGFR tyrosine kinase inhibitors. The development of combination therapies targeting both EGFR mutations and MET amplification is a critical area of research to overcome this resistance and improve patient prognosis in advanced disease.
Trial design
The SACHI study (Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification) is a clinical trial designed to evaluate a novel treatment strategy. This interim analysis focuses on patients with advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China. The study compares the efficacy and safety of savolitinib plus osimertinib against standard chemotherapy in this specific patient population.
What this means
The publication of an interim analysis from the SACHI study provides an early look into the potential of combining savolitinib with osimertinib for patients facing advanced, EGFR mutation-positive, MET-amplified NSCLC. This patient group often experiences disease progression on EGFR-targeted monotherapy due to resistance mechanisms like MET amplification. While specific results are not detailed here, an interim analysis can offer valuable insights into the ongoing trial's progress and the potential for this combination to address an unmet medical need. Further data from the completed trial will be essential to fully understand the long-term efficacy and safety profile of this therapeutic approach.
Source
The information regarding this interim analysis was published on January 1, 2026, and sourced from PubMed, referencing a publication in The Lancet. The article is titled 'Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analys' and is accessible via pubmed.ncbi.nlm.nih.gov.